Mike Knight, an executive in a semiconductor firm, learns that his eight-year-old son Tim has a rare form of brain cancer. Tim's best hope for long-term survival is a drug called Supragrel. Unfortunately, Supragrel is still in early clinical trials and may reach the market too late. Mike makes the agonizing decision to quit his job and go to...